Current status, complications and prospects of fecal microbiota transplantation therapy

Abstract

Currently, the emergence of highly virulent mutants in Europe and the United States has caused refractory recurrent Clostridium diffi cile infection (RCDI) to be a problem in clinical practice. In 2013, the Netherland group demonstrated breakthrough therapeutic effi cacy in fecal microbial transplant (FMT) treatment clinical trials for RCDI, and FMT treatment is rapidly gaining attention. In addition to RCDI, FMT treatment has been attempted in various gastrointestinal diseases such as infl ammatory bowel disease, irritable bowel syndrome and chronic constipation, as well as extragastrointestinal diseases. In this review, I would like to describe the current status, complications and prospects of FMT treatment. Review Article